B
Bull
Bull · 25%CLLS
$3.65
Szenariopreis
$3.400
-0.148 (-4.36%)Zum Schluss
Loading chart…
- High
- 3.570
- Open
- 3.480
- VWAP
- 3.46
- Vol
- 5.72K
- Mkt Cap
- 133.84M
- Low
- 3.400
- Amount
- 19.77K
- EV/EBITDA, TTM
- -2.02
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
AI analysis of Cellectis SA (CLLS)
buyCellectis SA is a good buy right now due to its recent FDA RMAT designation for its CAR-T therapy, which has shown a 67% objective response rate in trials. The current price of $3.40 is significantly lower than the analyst price target of $9, suggesting substantial upside potential. Additionally, the stock has gained 23.64% over the last 20 days, indicating positive momentum. However, the forward P/E ratio is 0, reflecting uncertainty in earnings projections, which is a risk to consider.
Analyst Ratings (6)
+105.88% upside
Buy
5 Buy
1 Hold
0 Sell
Current: 3.40
Tief
4.00
Durchschnitt
7.00
Hoch
9.00
Barclays
Overweight
$9
2026-05-28
Barclays
2026-05-28
Kursziel
$9
Overweight
Wells Fargo
Equal Weight
$4
2025-10-20
Wells Fargo
2025-10-20
Kursziel
$4
Equal Weight
Barclays
Overweight
$4
2025-05-13
Barclays
2025-05-13
Kursziel
$4
Overweight
Barclays
Buy
$5
2024-11-05
Barclays
2024-11-05
Kursziel
$5
Buy
Oppenheimer
Buy
$10
2024-06-12
Oppenheimer
2024-06-12
Kursziel
$10
Buy
Bewertungskennzahlen
The current forward P/E ratio for Cellectis SA (CLLS) is 0.00, compared to its 5-year average forward P/E of -1.29.
Alphio AI Price Scenarios for CLLS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding CLLS
Event-Zeitleiste
News
9.508-07NASDAQ.COMCellectis Reports Q2 2026 Financial Results and Pipeline Updates
9.508-06GlobenewswireCellectis Reports Clinical Progress and Financial Results
8.508-06NewsfilterCellectis Receives FDA RMAT Designation, Advances Clinical Trials
8.508-05GlobenewswireCellectis Updates on Listing Information
9.507-30GlobenewswireCellectis to Report Q2 2026 Financial Results on August 6
CLLS FAQ — answered by Alphio AI
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others. It operates in the Healthcare sector.
Cellectis SA is a good buy right now due to its recent FDA RMAT designation for its CAR-T therapy, which has shown a 67% objective response rate in trials. The current price of $3.40 is significantly lower than the analyst price target of $9, suggesting substantial upside potential. Additionally, the stock has gained 23.64% over the last 20 days, indicating positive momentum. However, the forward P/E ratio is 0, reflecting uncertainty in earnings projections, which is a risk to consider.
6 analysts cover CLLS: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 7.00.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.